XM does not provide services to residents of the United States of America.

G
G

Gilead

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Reuters - 2 days ago

Nasdaq top and bottom performing stocks at about 03:45 p.m. EST

BUZZ - Nasdaq top and bottom performing stocks at about 03:45 p.m. EST Nasdaq 100 .NDX Top Performers Percent Change PDD Holdings Inc PDD.OQ +3.1% Workday Inc WDAY.OQ +2.6% Dollar Tree Inc DLTR.OQ +2.0% Gilead Sciences Inc GILD.OQ +1.9% Palo Alto Networks Inc PANW.OQ +1.9% Bottom Performers Percent Change Lucid Group Inc LCID.OQ -4.5% Warner Bros Discovery Inc WBD.OQ -3.2% NVIDIA Corp NVDA.OQ -3.2% Atlassian Corp TEAM.OQ -2.8% Advanced Micro Devices Inc AMD.OQ -2.7% The Nasdaq 100 .NDX lost 99.2
G
N
A
D
U
A
P
W
Reuters - 4 days ago

Swiss stocks - Factors to watch on November 29

REFILE-Swiss stocks - Factors to watch on November 29 Removes reference to UBS report on billionaires, which is due on Thursday, not Wednesday. ZURICH/BERLIN, Nov 29 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Wednesday: JULIUS BAER BAER.S CEO Philipp Rickenbacher will speak on the AGM board agenda for January 2024, challenges, opportunities and risks for the next 12 months at the FT conference.
A
G
G
N
N
R
U
J
Reuters - 4 days ago

US FDA investigating safety risk of T cancer therapies

UPDATE 4-US FDA investigating safety risk of CAR-T cancer therapies Adds details on treatment, comments by CAR-T scientist, ASCO expert and Novartis, adds closing share prices, paragraphs 1-10, 13, 15-17 By Pratik Jain Nov 28 (Reuters) - The U.S. Food and Drug Administration (FDA) said on Tuesday it was investigating cancer therapies made by Gilead Sciences GILD.O , Johnson & Johnson JNJ.N , Novartis NOVN.S and others over the risk of hospitalizations and death due to a serious safety issue.
G
N
Reuters - 4 days ago

T therapy developers fall amid U.S. FDA investigation

BUZZ-CAR-T therapy developers fall amid U.S. FDA investigation ** Shares of CAR-T cell therapy developers Gracell Biotechnologies GRCL.O and Autolus Therapeutics AUTL.O fall ~17% and ~11%, respectively, after U.S. FDA launches investigation into the safety risk of the therapies ** FDA says it was investigating CAR-T therapies made by companies such
G
Reuters - 4 days ago

US FDA investigating safety risk of T cancer therapies

UPDATE 3-US FDA investigating safety risk of CAR-T cancer therapies Updates share movement, adds background in paragraph 3 By Pratik Jain Nov 28 (Reuters) - The U.S. Food and Drug Administration (FDA) said on Tuesday it was investigating cancer therapies made by companies such as Gilead Sciences GILD.O , Johnson & Johnson JNJ.N and Novartis NOVN.S over the risk of hospitalizations and death due to a serious safety issue.
G
N

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.